Trials / Unknown
UnknownNCT06173440
Management of an Imipenem-resistant Acinetobacter Baumannii Alert in a French University Hospital
Management of an Imipenem-resistant Acinetobacter Baumannii Alert in a French University Hospital: A Retrospective Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 148 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Colonization with imipenem-resistant Acinetobacter baumannii (IBA) is an unfavorable event for the patient, especially in intensive care. Indeed, it exposes the patient to the risk of developing serious infections, extremely difficult to treat. ABRI is a particularly resistant bacterium in the environment. When an ABRI epidemic occurs in a department as central to the hospital as a surgical resuscitation department, the control of such an event can be extremely complex. There are few clear and detailed descriptions in the literature of how to manage this type of outbreak, let alone an ABRI outbreak of this magnitude.
Conditions
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2023-12-15
- Last updated
- 2023-12-15
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06173440. Inclusion in this directory is not an endorsement.